These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36718010)

  • 21. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.
    Hong T; Zhang M; Fan J
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
    J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
    Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
    Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of different induction immunosuppression protocols on patient survival, graft survival and acute graft rejection after kidney transplantation.
    Vnucak M; Granak K; Beliancinova M; Gala I; Chrapekova M; Kovacova A; Bena L; Zilinska Z; Dedinska I
    Bratisl Lek Listy; 2022; 123(10):730-735. PubMed ID: 35913008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990-2009).
    Cai J
    Clin Transpl; 2009; ():83-101. PubMed ID: 20524278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience.
    Trofe J; Stratta RJ; Egidi MF; Lo A; Gaber LW; Shokouh-Amiri MH; Grewal HP; Honaker M; Hardinger K; Alloway RR; Gaber AO
    Clin Transplant; 2002; 16 Suppl 7():34-44. PubMed ID: 12372042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk.
    Masset C; Boucquemont J; Garandeau C; Buron F; Morelon E; Girerd S; Ladrière M; Mourad G; Garrigue V; Cassuto E; Albano L; Foucher Y; Dantal J;
    Transplantation; 2020 Mar; 104(3):613-622. PubMed ID: 31283665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
    Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD
    Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases.
    Kaufman DB; Leventhal JR; Stuart J; Abecassis MM; Fryer JP; Stuart FP
    Transplantation; 1999 Feb; 67(4):586-93. PubMed ID: 10071032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
    Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
    Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
    Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
    Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.